Active registration studies for BCR antagonists
| Agent . | Study title/number . | Clinicaltrials.gov identifier . | Phase . | Indication . | Design . |
|---|---|---|---|---|---|
| Ibrutinib | Resonate/PCYC-1112-CA | NCT01578707 | 3 | Relapsed/refractory | Ofatumumab vs ibrutinib |
| Resonate-2/PCYC-1115-CA | NCT01722487 | 3 | Treatment-naïve | Chlorambucil vs ibrutinib | |
| Resonate-17/PCYC-1117-CA | NCT01744691 | 2 | Relapsed/refractory del(17p)+ | Ibrutinib | |
| Idelalisib | GS-US-312-0115 | NCT01569295 | 3 | Relapsed/refractory | Bendamustine, rituximab ± idelalisib |
| GS-US-312-0116 | NCT01539512 | 3 | Relapsed/refractory | Rituximab ± idelalisib | |
| GS-US-312-0119 | NCT01659021 | 3 | Relapsed/refractory | Ofatumumab ± idelalisib |
| Agent . | Study title/number . | Clinicaltrials.gov identifier . | Phase . | Indication . | Design . |
|---|---|---|---|---|---|
| Ibrutinib | Resonate/PCYC-1112-CA | NCT01578707 | 3 | Relapsed/refractory | Ofatumumab vs ibrutinib |
| Resonate-2/PCYC-1115-CA | NCT01722487 | 3 | Treatment-naïve | Chlorambucil vs ibrutinib | |
| Resonate-17/PCYC-1117-CA | NCT01744691 | 2 | Relapsed/refractory del(17p)+ | Ibrutinib | |
| Idelalisib | GS-US-312-0115 | NCT01569295 | 3 | Relapsed/refractory | Bendamustine, rituximab ± idelalisib |
| GS-US-312-0116 | NCT01539512 | 3 | Relapsed/refractory | Rituximab ± idelalisib | |
| GS-US-312-0119 | NCT01659021 | 3 | Relapsed/refractory | Ofatumumab ± idelalisib |